Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05357651 Recruiting - Lymphoma Clinical Trials

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)

Start date: August 12, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.

NCT ID: NCT05355051 Recruiting - Hodgkin's Lymphoma Clinical Trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Start date: October 5, 2022
Phase: Phase 2
Study type: Interventional

This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.

NCT ID: NCT05354362 Terminated - Clinical trials for Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

MATCH
Start date: March 2, 2022
Phase: Phase 1
Study type: Interventional

This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

NCT ID: NCT05352828 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

ACTION
Start date: July 25, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.

NCT ID: NCT05351593 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Start date: June 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that Tafasitamab enhances blood-brain barrier permeability, a potential property that could have broad clinical implications.

NCT ID: NCT05351346 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Genotype-guided Treatment in DLBCL

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

NCT ID: NCT05349266 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Start date: March 18, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, single center study to assess the efficacy and safety of ThisCART19A in adult with Non-Hodgkins Lymphoma in China.

NCT ID: NCT05348213 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

R-ICE+X
Start date: May 16, 2022
Phase: Phase 2
Study type: Interventional

A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.

NCT ID: NCT05347641 Not yet recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to clarify the clinical and biological factors affecting the efficacy

NCT ID: NCT05346809 Recruiting - Multiple Myeloma Clinical Trials

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.